🚨Trade Alert 🚨 NNVC

🚨Trade Alert 🚨 NNVC͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ The company’s game-changing lead drug candidate against Covid-19 makes [NanoViricides, Inc. (NYSE: NNVC)]( a compelling growth story to zoom in on! Greetings All, Covid-19 may not be making as many headlines as it once did, but the world isn’t out of the woods yet. Infections and deaths from the virus are still occurring every day in the US, although many people are acting like it’s all over. The virus is still a deadly disease. There are still [over 170,000 infections]( weekly, as well as close to 3,000 hospitalizations and 1,800 deaths in the USA alone. COVID is still the biggest viral public health threat today! One quietly-trading NYSE company is about to begin clinical trials for a pan-coronavirus drug to help defeat the virus once and for all…. put NanoViricides Inc. (NYSE: NNVC) on your radar! This leading biopharmaceutical company is developing nanotechnology-based antiviral therapeutics and has been working on a pan-coronavirus antiviral to fulfill an unmet medical need. Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. Imagine a pan-coronavirus drug that is safe enough to be used by anyone and is highly effective remains an unmet medical need….. That’s what NNVC is developing. The company has been a drug discovery company for many years while it has looked to perfect its patented nanoviricide technology, a platform technology that deploys a novel mechanism to combat viruses. With this unique technology, NNVC has reported developing a strong R&D pipeline of many antiviral drugs. It’s no surprise that the company boasts [a $5.25 price target!]( This price target represents a +352.59% increase from the last price of 1.16. So why pay attention to NNVC in particular? The company is transitioning into becoming a clinical-stage pharmaceutical company and its clinical trials of NV-CoV-2, the Company’s pan-coronavirus drug, are now [imminent]( The drug has already successfully [completed]( the preclinical safety and effectiveness studies, and the Company has already set up cGMP manufacturing for the clinical drug products. The best part? NNVC’s drug may work against all current and future Covid variants! NV-CoV-2 is a broad-spectrum antiviral that looks to treat most human coronaviruses and will maintain its effectiveness as the variants mutate. This may mark a major step in the fight to find a permanent solution to COVID. Developing a drug that works against multiple COVID variants is key because as each variant mutates and spreads it has the [risk]( of further widespread outbreaks causing an endemic or even a future pandemic. This may be the most exciting time to be paying attention to NNVC. The company’s lead coronavirus drug candidate could become a game changer in fighting the virus and could quickly put NNVC on the map! NV-CoV-2 was found to work against many unrelated coronaviruses. So variants of SARS-CoV-2 (that causes COVID) are highly unlikely to be able to escape it! [( NanoViricides, Inc. NYSE: NNVC A New Era in Targeted Anti-Viral Therapeutics. NanoViricides, Inc. (NYSE: NNVC) is a development stage company moving to clinical-stage that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Their platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. NV-CoV-2: NanoViricides, Inc. (NYSE: NNVC) is pursuing a clinical trial application for its lead drug candidate for the treatment of COVID-19, NV-CoV-2. This drug candidate is designed to act by a novel mechanism of action, that they call "Re-infection Blocker". NV-CoV-2 was found to be a broad-spectrum, pan-coronavirus drug candidate in pre-clinical studies. NanoViricides Drug NV-CoV-2 is Unique Antiviral medication is an important way of coping with viral infections, other than vaccines and antibodies, as we all know from HIV. These drugs help the body [fight off]( at the cellular level. Many people have no idea that there are significant issues with the antivirals currently on the market for treating COVID. These include [Molnupiravir]( Merck & Co. (NYSE: MRK), [Paxlovid]( Pfizer Inc. (NYSE: PFE) and [Remdesivir]( from Gilead Sciences, Inc. (NASDAQ: GILD), which either have limited effectiveness in treating the disease or carry the risk of serious side effects or both. Of note, they all have significant limitations on which category of patients can be helped. Unlike the existing COVID drugs, NanoViricides’ drug NV-CoV-2 caters to the needs of ALL patients. The Company has developed oral syrup and oral gummies for use in mild to moderate disease (out-patients). It has developed an injectable solution that can be injected, inhaled or infused, for use in severely ill or hospitalized patients. Having these multiple formulations gives the drug a broad range of applications. The company also has the ability to manufacture clinical quantities of the drug products for clinical trials in its own “current Good Manufacturing Practices (cGMP)”-compliant facility, enabling time and cost savings. NanoViricides, Inc. (NYSE: NNVC) is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility! The global antiviral market was [worth]( billion in 2018 and is expected to grow to $79.8 billion at a compound annual growth rate (CAGR) of 6.7% from 2019 to 2026. It’s obvious the market is lucrative and allows NNVC to zoom in on a tremendous population. MORE REASONS TO HAVE [NNVC]( ON YOUR RADAR INCLUDE: - The company is led by the renowned inventor of nanoviricides technology, Dr. Anil Diwan, and is managed by a highly effective team who have decades of entrepreneurial, pharmaceutical, and nanomedicine experience. - Strong P&E assets comprise the company’s cGMP-capable manufacturing and R&D facility. - The company’s drug products could significantly change the world if and they contend when hit the market. - Over 15+ years of experience in nanomedicine and antiviral therapy developments. - Fast moving drug candidate developments for the treatment of SARS-CoV-2 in patients. - A strong, diverse, and promising product pipeline that addresses the world’s most infamous and infectious viruses. - The antiviral therapy and nanomedicine market is expected to experience exponential growth in the coming years as more viruses emerge. - The company’s developments are sustainable beyond COVID-19 as their diverse product pipeline targets several markets simultaneously: As COVID-19 continues to spread across the globe, increased demand for nanomedicine has led to the strong growth of the global nanomedicine market. NNVC reported that as of December 31, 2022, they had cash and cash equivalent current assets balance of approximately $11.5 Million. In addition, they reported approximately $8.4 Million in Property and Equipment (P&E) assets, net of depreciation and amortization from $14.7 Million in P&E assets before depreciation. The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The company believes they have sufficient funds to complete initial human clinical trials for NV-CoV-2. NV-CoV-2 addresses the unmet need for a safe and effective treatment that can be used in otherwise healthy patients as well as in children, based on its strong safety and effectiveness observed in animal studies. With production of the drug now underway, NNVC could quickly start gaining Wall Street attention and with a $5.25 price target, may see upside in the TRIPLE DIGITS! Copyright 2022 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in NNVC. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding NNVC with a start date of 4/04/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042